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ABSTRACT
Parkinson’s disease (PD) is a progressive neurological disorder
characterized by a selective loss of dopamine (DA) neurons in
the substantia nigra (SN). Although current therapy can control
symptoms of this disorder, there is no effective therapy avail-
able to halt its progression. Recently, neuroinflammation has
been recognized as an important contributor to the pathogen-
esis of PD, and nuclear factor-B (NF-B) plays a key role in
regulating neuroinflammation. Hence, the modulation of NF-B
pathway may have therapeutic potential for PD. Activation of
NF-B depends on the phosphorylation of its inhibitor, IB, by
the specific IB kinase (IKK) subunit IKK-. Compound A (7-[2-
(cyclopropylmethoxy)-6-hydroxyphenyl]-5-[(3S)-3-piperidinyl]-1,
4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one hydrochloride), a
potent and selective inhibitor of IKK-, has recently been re-
ported to provide cardioprotection through specific suppres-
sion of NF-B signaling. The present study, for the first time,
elucidates neuroprotective effects of compound A. Daily sub-
cutaneous injection of compound A (1 mg/kg) for 7 days inhib-
ited the activation of microglia induced by nigral stereotaxic
injection of lipopolysaccharide (LPS) and significantly attenu-
ated LPS-induced loss of DA neurons in the SN. In vitro mech-
anistic studies revealed that neuroprotective effects of com-
pound A were mediated by 1) suppressing the activity of
microglial NADPH oxidase and decreasing the production of
reactive oxygen species, and 2) inhibiting NF-B-mediated
gene transcription of various proinflammatory mediators in mi-
croglia via IKK- suppression. These findings indicate that com-
pound A afforded potent neuroprotection against LPS-induced
neurodegeneration through selective inhibition of NF-B activa-
tion and may be of potential benefit in the treatment of PD.
Parkinson’s disease (PD) is the second most common neu-
rodegenerative disorder, and it is characterized by a slow and
progressive loss of dopamine (DA) neurons in the substantia
nigra (SN) pars compacta of the ventral midbrain and the
subsequent loss of DA content in the striatum. The cardinal
clinical symptoms of PD include dyskinesia, resting tremor,
rigidity, and gait disturbance. Current therapeutic interven-
tions are limited to alleviating the symptoms of PD, and they
fail to halt the progression of neurodegeneration (Gao et al.,
2003a).
Although oxidative stress, mitochondrial dysfunction, ex-
citotoxicity, and apoptotic processes have been identified as
being involved in neuronal degeneration (Nagatsu and
Sawada, 2006), the mechanisms responsible for the progres-
sive feature of neurodegeneration are not fully understood.
In recent years, increasing evidence has strongly sug-
gested that neuroinflammation is an important contribu-
tor to the pathogenesis of neurodegenerative diseases,
such as PD, Alzheimer’s disease, and multiple sclerosis.
The hallmark of brain neuroinflammation is the activation
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of microglia (Hirsch and Hunot, 2009). Microglia are the
resident immune cells in the brain and serve critical roles in
immune surveillance under normal conditions. Once acti-
vated after brain damage or exposure to inflammogen, mi-
croglia can release many proinflammatory and cytotoxic fac-
tors, including prostaglandins, cytokines, reactive oxygen
species (ROS), and reactive nitrogen species. The accumula-
tion of these factors is thought to contribute to the loss of DA
neurons. Subsequently, the continuing processes involved in
the dying/dead DA neurons, in turn, lead to the secondary
activation of microglia and further DA neuronal loss. Thus, a
vicious “self-propelling” cycle is created, which causes pro-
gressive neurodegeneration (Gao and Hong, 2008). Taken
together, strong evidence shows a pivotal role of neuroinflam-
mation in the manifestation of PD, and thus the inhibition of
microglia-mediated inflammatory processes is becoming a
promising therapeutic potential for the treatment of PD.
It is well known that nuclear factor-B (NF-B) is an
important regulator of brain inflammation. For example,
NF-B plays a critical role in the regulation of microglial
production of several proinflammatory factors including tu-
mor necrosis factor (TNF)-, interleukin (IL)-1, cyclooxy-
genase-2, and nitric oxide (NO) (Jana et al., 2001; Lee et al.,
2004; Moriyama et al., 2006; Werner et al., 2008). NF-B
activation is detected within the SN of PD patients and a PD
animal model created by 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP) (Hunot et al., 1997; Ghosh et al., 2007).
Of particular interest is marked colocalization of p65 with
CD11b-positive activated microglia in the SN of postmortem
PD brains (Ghosh et al., 2007). Moreover, selective inhibition
of NF-B activation suppressed microglial activation and
prevented DA neuronal loss against MPTP-intoxicated PD
mice (Ghosh et al., 2007). Similarly, inhibition of NF-B and
suppression of cyclooxygenase-2 activity are involved in the
neuroprotection of pioglitazone against lipopolysaccharide
(LPS) insult on DA neurons (Xing et al., 2007).
In resting conditions, NF-B is sequestered in the cytosol by
binding to its inhibitor, IB. Activation of NF-B requires the
activity of IB kinase (IKK) complex, in a manner dependent
mainly on the IKK- catalytic subunit (Karin, 1999). A variety
of inflammatory stimuli, including endotoxin (e.g., LPS) and
cytokines, induce activation and nuclear translocation of NF-B
after rapid phosphorylation, degradation, and release of IB
(Zhang and Ghosh, 2001). Compound A (7-[2-(cyclopropylme-
thoxy)-6-hydroxyphenyl]-5-[(3S)-3-piperidinyl]-1,4-dihydro-2H-
pyrido[2,3-d][1,3]oxazin-2-one hydrochloride) is a selective in-
hibitor of IKK- (Ziegelbauer et al., 2005). It prevents
pulmonary inflammation (Moss et al., 2008) and attenuates
myocardial injury and dysfunction after ischemia–reperfusion
injury, in which specific suppression of NF-B signaling and
consequent decrease in serum levels of TNF and IL-6 under-
lie cardioprotection (Ziegelbauer et al., 2005; Moss et al.,
2007). In the present study, we report that compound A
exerted neuroprotective effects against LPS-induced neuro-
toxicity both in vitro and in vivo. Mechanistic studies showed
that the neuroprotective effects of compound A were medi-
ated by suppressing the activity of NADPH oxidase [phago-
cytic oxidase (PHOX)] and the activation of NF-B cascade
signaling pathway in activated microglia through specific
IKK- inhibition.
Materials and Methods
Reagents. Compound A (Bay 65-1942) was purchased from Thera-
Logics Inc. (Chapel Hill, NC). All cell culture materials were pur-
chased from Invitrogen (Carlsbad, CA). LPS (Escherichia coli strain
O111:B4) and the fluorescence probe dichlorodihydrofluorescein di-
acetate (DCFH-DA) were obtained from Calbiochem (San Diego, CA).
1-Methyl-4-phenylpyridinium (MPP), cytosine -D-arabinofurano-
side, leu-leu methyl ester, and superoxide dismutase (SOD) were
purchased from Sigma-Aldrich (St. Louis, MO). [3H]DA (30 Ci/mM)
was purchased from PerkinElmer Life and Analytical Sciences
(Waltham, MA). The polyclonal antityrosine hydroxylase (TH) anti-
body was a gift from Dr. John Reinhard (GlaxoSmithKline, Research
Triangle Park, NC). Monoclonal antibody against the CR3 comple-
ment receptor (OX-42) was obtained from BD Pharmingen (San
Diego, CA). A vectastain avidin–biotin complex kit and biotinylated
secondary antibody were obtained from Vector Laboratories (Burlin-
game, CA). Also used were: WST-1 (Dojindo Laboratories, Gaithers-
burg, MD), TRIzol reagent (Invitrogen), RNeasy Kit (QIAGEN, Va-
lencia, CA), SYBR green polymerase chain reaction (PCR) master
mix (Applied Biosystems, Foster City, CA), and an enhanced chemi-
luminescence kit (GE Healthcare, Chalfont St. Giles, UK).
Animals and Treatment. Male Fisher rats (200–225 g) and
timed-pregnant Fisher F344 rats were obtained from Charles River
Laboratories, Inc. (Wilmington, MA). Experimental use of the ani-
mals was performed in strict accordance with National Institutes of
Health Guidelines. To investigate the effect of compound A on LPS-
induced neurotoxicity, male rats received a single LPS injection (5 g
in 2 l of saline) into the SN pars compacta on one side of the brain,
followed by the coordinates 4.8 mm posterior to bregma, 1.7 mm
lateral to the midline, and 8.2 mm ventral to the surface of the skull
(Liu et al., 2000b). Compound A (1 mg/kg/day s.c.) was administrated
once a day for 7 consecutive days beginning 30 min before LPS
injection. Animals were sacrificed 1 day after the last compound A
treatment.
Primary Rat Mesencephalic Neuron-Glia and Neuron-
Astrocyte Cultures. Primary neuron-glia cultures were prepared
from the ventral mesencephalic tissues of embryonic day 14 and 15
rats as described previously (Zhang et al., 2006). In brief, dissociated
cells were seeded at 5  105/well and 1  105/well in poly-D-lysine-
coated 24- and 96-well plates, respectively. The cultures were main-
tained at 37°C in a humidified atmosphere of 5% CO2 and 95% air in
maintenance medium that was made up of minimum essential me-
dium containing 10% heat-inactivated fetal bovine serum, 10% heat-
inactivated horse serum, 1 g/liter glucose, 2 mM L-glutamine, 1 mM
sodium pyruvate, 100 M nonessential amino acids, 50 U/ml peni-
cillin, and 50 g/ml streptomycin. Seven-day-old cultures were used
for drug treatments. At the time of treatment, immunocytochemical
analysis indicated that the rat neuron-glia cultures consisted of 10%
microglia, 50% astrocytes, 40% neurons, and 1% TH-immunoreactive
neurons. For treatment, cultures were changed to treatment medium
composed of minimum essential medium, 2% fetal bovine serum, 2%
horse serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 50 U/ml
penicillin, and 50 g/ml streptomycin. Primary neuron-astrocyte
cultures were obtained by suppressing microglia proliferation with
1.5 mM leu-leu methyl ester added to neuron-glia cultures 1 day
after seeding the cells as described previously (Liu et al., 2000a).
Three days later, cultures were changed back to maintenance me-
dium and used for treatment 7 days after initial seeding. The per-
centage of microglia in the cultures was 1%.
Primary Microglia-Enriched Cultures. Primary microglia-en-
riched cultures were prepared from the whole brains of 1-day-old rat
pups as described previously (Zhang et al., 2006). After a confluent
monolayer of glia cells had been obtained, microglia were shaken off
and immunocytochemical analysis indicated that the cultures were
95 to 98% pure for microglia. Cells were seeded at 5  105/well and
1  105/well in 24- and 96-well plates, respectively, and used for
treatment the next day.
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Primary Midbrain Neuron-Enriched and Reconstituted
Neuron-Microglia Cultures. Midbrain neuron-enriched cultures
were established as described previously. One day after seeding,
cytosine -D-arabinofuranoside was added to a final concentration of
6 to 8 M to suppress glia proliferation. The 7-day-old neuron-
enriched cultures were composed of 90% neurons, 10% astrocytes,
and 0.1% microglia. The reconstituted cultures were established by
adding 10% (5  104/well) of primary microglia back to neuron-
enriched cultures as described previously (Liu et al., 2000a).
[3H]DA Uptake Assay. [3H]DA uptake assay was performed as
described previously (Zhang et al., 2006). Cultures were incubated
for 20 min at 37°C with 1 M [3H]DA in Krebs-Ringer buffer. Cells
were washed with ice-cold Krebs-Ringer buffer, and then collected in
1 N NaOH. Radioactivity was determined by liquid scintillation
counting. Nonspecific DA uptake observed in the presence of mazin-
dol (10 M) was subtracted.
Immunocytochemical Staining. Immunostaining was per-
formed as described previously (Liu et al., 2000a). In brief, 3.7%
formaldehyde-fixed cells were treated with 1% hydrogen peroxide
followed by sequential incubation with blocking solution, after which
the cultures were incubated overnight at 4°C with primary anti-TH
antibody (1:5000). Cells were incubated with biotinylated secondary
antibody for 1 h followed by incubation with Vectastain avidin–
biotin complex reagents for 40 min, and then color was developed
with 3,3-diaminobenzidine. For morphological analysis, the images
were recorded with a charge-coupled device camera (Dage-MTI,
Michigan City, IN) and operated with MetaMorph software (Molec-
ular Devices, Sunnyvale, CA). For visual counting of TH-positive
neurons, four representative areas per well of the 24-well plate were
counted. In each condition, three wells were used for cell counting.
Nitrite, TNF-, and IL-1 Assay. The production of NO was
accessed by measuring the accumulated levels of nitrite in the cul-
ture supernatants with Griess reagent. The release of TNF and
IL-1 was measured with immunosorbent assay kits from R&D
Systems (Minneapolis, MN).
Real-Time Reverse Transcription-PCR. Total RNA was isolated
by using TRIzol reagent and purified with a RNeasy Kit. The primers
were designed with ABI Primer Express software (Applied Biosystems,
Foster City, CA). The sequences of the primers were: -actin, GTAT-
GACTCCACTCACGGCAAA (F), GGTCTCGCTCCTGGAAGATG (R);
inducible NO synthase (iNOS), ACATCAGGTCGGCCATCACT (F),
CGTACCGGATGAGCTGTGAATT (R); TNF, GACCCTCACACTCA-
GATCATC-TTCT (F), CCTCCACTTGGTGGTTTGCT (R); and IL-1,
CTGGTGTGTGACGTTCCC-ATTA (F), CCGACAGCACGAGGCTTT (R).
Total RNA was reverse-transcribed with murine leukemia virus
reverse transcriptase and oligo(dT) primers. The SYBR Green PCR
Master Mix was used for real-time PCR analysis. The relative dif-
ferences in the expression of these inflammatory factors among
groups were expressed by using cycle time values as follows: the cycle
time values of the interested genes were first normalized with -ac-
tin of the same sample, and then the relative difference between
control and each treatment group was calculated and expressed as a
relative reduction, setting the LPS at 100%.
Superoxide Assay. The production of superoxide was accessed
by measuring the SOD-inhibitable reduction of the tetrazolium salt
WST-1. Primary microglia-enriched cultures in 96-well plates were
washed twice with Hanks’ balanced salt solution (HBSS) without
phenol red. Cells were then incubated at 37°C for 30 min with vehicle
control or compound A in HBSS (50 l/well). Subsequently, 50 l of
HBSS with and without SOD (50 U/ml) was added to each well along
with 50 l of WST-1 (1 mM) in HBSS and 50 l of vehicle or LPS (10
ng/ml). The absorbance at 450 nm was read with a SpectraMax Plus
microplate spectrophotometer (Molecular Devices) every 5 min for
1 h. The different absorbance observed in the presence and absence
of SOD was considered to be the amount of produced superoxide.
Intracellular ROS Assay. Intracellular ROS were determined
by using the DCFH-DA assay. Primary microglia-enriched cultures
were seeded in a 96-well plate and then exposed to DCFH-DA for 1 h,
followed by pretreatment with compound A for 30 min and then
treatment with HBSS containing LPS. After incubation at 37°C for
30 min, the fluorescence was read at 485 nm for excitation and 530
nm for emission by using a SpectraMax Gemini XS fluorescence
microplate reader (Molecular Devices).
Western Blot Analysis. For subcellular fractions, primary mi-
croglia-enriched cultures were lysed in hypotonic lysis buffer incu-
bated on ice for 30 min, and then subjected to homogenization. The
lysates were loaded onto a sucrose gradient in lysis buffer and
centrifuged at 1600g for 15 min. The supernatant above the sucrose
gradient was used as the cytosolic fraction after centrifugation at
150,000g for 1 h. The pellet was solubilized in hypotonic lysis buffer
and used as the membranous fraction. For extracting the whole cell
lysates, microglia-enriched cultures were washed with cold phos-
phate-buffered saline and lysed with cell lysis buffer. The lysates
were incubated on ice for 30 min and then centrifuged at 12,000g for
25 min. Protein levels were quantified by using BCA assay. Mem-
branes were blocked with 5% nonfat milk and then incubated with
the following primary antibodies: anti--actin, anti-iNOS, anti-phos-
pho-p65, anti-p65, anti-phospho-IB, anti-IB, anti-phospho-IKK–,
anti-IKK-, anti-phospho-ERK1/2, anti-ERK1/2, anti-phospho-p38,
anti-p38, anti-phospho-JNK, and anti-JNK at 1:1000 dilution (Cell
Signaling Technology Inc., Danvers, MA); anti-p47PHOX at 1:1000
dilution (Millipore, Billerica, MA); anti-gp91PHOX at 1:1000 dilution
(BD Biosciences, San Jose, CA); anti-Iba-1 at 1:1000 dilution (Wako
Pure Chemicals, Tokyo, Japan), and horseradish peroxidase-conju-
gated secondary antibodies at 1:2500 dilution (GE Healthcare). The
blots were developed with enhanced chemiluminescence reagent.
Immunohistochemistry and Cell Counting in the SN of Rat.
Rat brains were cut on a horizontal sliding microtome into 35-m
transverse free-floating sections. A total of 36 consecutive brain
slices throughout the entire SN was collected, and every 6th section
was processed for the immunocytochemical detection. DA neurons
were recognized with an anti-TH antibody and microglia with OX-42
by using the avidin–biotin complex peroxidase method described
previously. Digital images of TH-positive neurons and microglia in
the SN were acquired on an Olympus microscope (Olympus, Tokyo,
Japan) using an attached Polaroid digital microscope camera (Po-
laroid, Cambridge, MA). Quantification of TH-positive neurons was
performed through visually counting the number of TH-positive neu-
ronal cell bodies blindly by two investigators, and the results were
obtained from the average. The mean value for the number of SN
TH-positive neurons was then deduced by averaging the counts of six
sections for each animal.
Statistical Analysis. Data were expressed as mean 	 S.E. Sta-
tistical significance was analyzed by one-way analysis of variance,
followed by Bonferroni’s post hoc t test. A value of p  0.05 was
considered statistically significant.
Results
Compound A Protected DA Neurons Against LPS-
Induced Neurotoxicity. Mesencephalic neuron-glia cul-
tures were used to investigate whether LPS-induced neuro-
toxicity was inhibited by compound A. The cultures were
pretreated with compound A (0.025–0.1 M) for 30 min fol-
lowed by the application of LPS (10 ng/ml). Seven days later,
degeneration of DA neurons was determined by [3H]DA up-
take assay, immunocytochemical staining, and counting TH-
positive neurons. The [3H]DA uptake assay indicated that
LPS treatment reduced the capacity of the cultures to take
up DA by approximately 60% compared with the vehicle-
treated control cultures, and this reduction was prevented by
compound A in a concentration-dependent manner (Fig. 1A).
Consistent with results from the [3H]DA uptake assay, the
neuroprotective effects of compound A on LPS-induced neu-
824 Zhang et al.
rotoxicity were further confirmed by counting TH-positive
neurons (Fig. 1B). From the morphological analysis, LPS
treatment caused apparent damage in the neuritis of the
remaining DA neurons. Pretreatment of compound A (0.1
M), which by itself showed no effect, reversed LPS-induced
neurotoxicity (Fig. 1C).
To study the time course of compound A-elicited neuropro-
trection, [3H]DA uptake assay was performed 1, 3, 5 and 7
days after LPS treatment. A clear time-dependent decrease
of [3H]DA uptake was observed in LPS-treated cultures: 25,
50, and 60% at 3, 5, and 7 days after treatment, respectively.
The progressive decrease in [3H]DA uptake was prevented by
compound A pretreatment. Although the initial 20% decrease
in [3H]DA uptake 3 days after LPS treatment was not re-
stored by compound A, there was no further loss of [3H]DA
uptake at days 5 and 7 in the compound A-pretreated group
(Fig. 1D).
Microglia Were Indispensable to the Neuroprotec-
tive Effects of Compound A. To determine which cell type
mediated the neuroprotective effects of compound A, four
types of cultures including neuron-glia, neuron-microglia,
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Fig. 1. Compound A protected DA neurons against LPS-induced neurotoxicity. Rat primary mesencephalic neuron-glia cultures seeded in 24-well
culture plates at 5  105/well were pretreated with various concentrations of compound A for 30 min before the addition of 10 ng/ml LPS. A and B,
7 days later, the LPS-induced DA neurotoxicity was quantified by the [3H]DA uptake assay (A) and TH-positive neuron counting using immunocy-
tochemical analysis (B). C, representative images of immunostaining from three experiments are shown. Scale bar, 200 m. For the time course study,
the DA neurotoxicity was measured by [3H]DA uptake assay at 1, 3, 5 and 7 days after LPS treatment. Results are expressed as a percentage of the
vehicle control cultures and are the mean 	 S.E. from three independent experiments performed in triplicate. #, p  0.05 compared with control
cultures; , p  0.05 compared with LPS-treated cultures.
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cultures were pretreated with compound A (0.1 M) 30 min
before 0.5 M MPP application. MPP, the active metabo-
lite of MPTP, kills DA neurons directly; toxic factors such as
-synuclein released by these dying/dead neurons in turn
contribute to reactive microgliosis and produce further neu-
rotoxicity (Jackson-Lewis and Smeyne, 2005). In these four
culture systems, MPP treatment reduced DA uptake by
approximately 40% compared with the vehicle control cul-
tures; the neurotoxicity was differentially attenuated by com-
pound A. In neuron-glia cultures and neuron-microglia cul-
tures, but not in neuron-enriched or neuron-astrocyte
cultures, neuroprotection was detected. These results dem-
onstrated that compound A-mediated neuroprotective effects
on DA neurons were microglia-dependent (Fig. 2).
Compound A Inhibited LPS-Induced Release of
Proinflammatory Factors in Neuron-Glia Cultures.
Neuroinflammation has been found to play an important role
in the loss of DA neurons in PD animal models and patients.
To investigate whether compound A was able to reduce the
microglia-mediated neuroinflammation, levels of several ma-
jor proinflammatory factors in supernatant and cells of neu-
ron-glia cultures were determined. As various proinflamma-
tory factors released from microglia vary in terms of time and
quantities, different time points were adjusted for their mea-
surement, such as TNF at 3 to 6 h and NO and IL-1 at 1
day after LPS treatment. The results demonstrated that
compound A significantly suppressed LPS-induced produc-
tion of proinflammatory factors measured from the superna-
tant of neuron-glia cultures (Fig. 3A). Likewise, as shown by
real-time RT-PCR (Fig. 3B), LPS (10 ng/ml) led to a notable
increase in mRNA expression of iNOS, TNF, and IL-1 in
neuron-glia cultures, which was significantly inhibited by
compound A. Western blot analysis for iNOS also showed
that compound A (0.1 M) attenuated LPS-induced increase
of iNOS protein expression (Fig. 3C).
Compound A Inhibited the Activation of NF-B Sig-
naling Pathway in LPS-Activated Microglia. NF-B is a
key transcriptional factor for the gene expression of proin-
flammatory factors, such as iNOS and TNF. Given the
dramatic suppression of the production of these proinflam-
matory mediators in microglia by compound A (Fig. 3), we
therefore investigated how compound A influences LPS-in-
duced activation of NF-B. Western blotting analysis re-
vealed that pretreatment with 0.1 M compound A signifi-
cantly inhibited LPS-elicited p65 and IKK- phosphorylation
in the primary microglia-enriched cultures (Fig. 4A). Fur-
thermore, LPS induced a rapid phosphorylation of cytosolic
IB followed by the degradation of IB, and these effects
were attenuated by the treatment of compound A (Fig. 4B).
Compound A Suppressed LPS-Induced Phosphory-
lation of MAPKs in Microglia. It is well known that the
MAPK pathway, including ERK1/2, p38, and JNK, is in-
volved in the regulation of immune responses (Bardwell,
2006). Therefore, we determined the effects of compound A on
the phosphorylation of MAPKs induced by LPS. Primary
microglia-enriched cultures were pretreated with 0.1 M
compound A for 30 min followed by LPS treatment for an-
other 15 min. Results showed that compound A treatment
inhibited LPS-induced phosphorylation of ERK1/2, p38
MAPK, and JNK in microglia (Fig. 5).
Compound A Attenuated LPS-Induced Production of
ROS Through the Inhibition of NADPH Oxidase Activ-
ity. Previous studies have found that ROS including extra-
cellular superoxide and intracellular ROS produced by LPS-
activated microglia appeared to be a pivotal effector of DA
neurodegeneration (Gao and Hong, 2008). To examine
whether compound A was capable of decreasing LPS-induced
production of ROS, primary microglia-enriched cultures were
used to measure the production of extracellular superoxide
and intracellular ROS. The results showed a significant in-
crease in the production of superoxide (Fig. 6A) and intracel-
lular ROS (Fig. 6B) in microglia stimulated with LPS, which
could be attenuated by the application of compound A.
Because NADPH oxidase is the key enzyme required for
the production of superoxide and intracellular ROS in acti-
vated immune cells, we then examined whether compound A
could inhibit NADPH oxidase activity. The activation of
NADPH oxidase requires translocation of phosphorylated cy-
tosolic subunits (p47PHOX, p67PHOX, and p40PHOX) to the cell
membrane and binding to cytochrome b558 composed of
p22PHOX and gp91PHOX. Western blot assay indicated an
increase in the immunoreactivity of p47PHOX in the mem-
brane of microglia after LPS stimulation in primary micro-
glia-enriched cultures, and this increase could be reduced by
treatment with compound A (Fig. 6C). These results indicate
that compound A decreased LPS-induced ROS production at
least partly through preventing the translocation of p47PHOX
from the cytosol to the membrane, thereby inhibiting
NADPH oxidase activation after LPS treatment.
Compound A Attenuated LPS Injection-Induced DA
Neuronal Loss and Microglia Activation in the SN.
After demonstrating neuroprotective effects of compound A
in neuron-glia cultures, we extended our findings in the in
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Fig. 2. Microglia were indispensable to compound A-medi-
ated neuroprotection. Four types of cultures prepared as
described in Materials and Methods were pretreated with
compound A (0.1 M) for 30 min followed by the adminis-
tration of MPP (0.5 M). Seven days after MPP treat-
ment, DA neurotoxicity was quantified by [3H]DA uptake
assay. Results are expressed as a percentage of vehicle
control cultures and are the mean 	 S.E. from three inde-
pendent experiments performed in triplicate. #, p  0.05
compared with control cultures; , p  0.05 compared with
MPP-treated cultures.
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trated 30 min before a single stereotaxical injection of LPS (5
g in 2 l of saline) into the rat SN pars compacta. After
seven daily injections of compound A, the brains were re-
moved, sectioned, and processed for quantification of DA
neurons by immunostaining using an anti-TH antibody. In-
jection of LPS led to a 60% loss of nigral TH-positive neurons
compared with the vehicle control, whereas the loss of TH-
neurons was only 20% in the compound A treatment group.
Morphologically, injection of compound A significantly pre-
vented the degeneration of TH-positive neuronal fibers in the
SN induced by LPS (Fig. 7).
To further investigate the basis of these neuroprotective
effects of compound A on LPS-induced neurodegeneration,
we detected the ability of compound A to inhibit LPS-induced
microglia activation. Seven days after LPS injection, the
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Fig. 3. Compound A inhibited the production of proinflammatory factors by LPS-activated microglia. Neuron-glia cultures were pretreated with
compound A (0.025–0.1 M) for 30 min and then stimulated with 10 ng/ml LPS. A, after 3 h (TNF) or 1 day (NO and IL-1), an aliquot of the
supernatant was collected for enzyme-linked immunosorbent assay analysis of TNF and IL-1 and Griess reaction analysis of nitrite levels. For
mRNA assessment, total RNA was harvested 1 h (TNF) or 3 h (iNOS and IL-1) after LPS treatment. B, the gene expressions were determined by
real-time reverse transcription–PCR. C, Western blot analysis revealed iNOS protein expression 1 day after LPS treatment. Results are expressed as
a percentage of the vehicle control cultures and are the mean 	 S.E. from three independent experiments performed in triplicate. #, p  0.05 compared
with control cultures; , p  0.05 compared with LPS-treated cultures.
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OX-42. Representative photomicrographs of OX-42-immuno-
reactive microglia are shown in Fig. 8A. In the vehicle control
sections, microglia exhibited a resting status with a ramified
morphology. Upon activation with LPS injection, microglia
were characterized by larger size, thicker processes, and
more rounded cell body. Microglia activation and morpho-
logic changes were significantly inhibited by the treatment of
compound A. The quantification of the OX-42 staining re-
vealed an approximate 30% reduction in the SN of rats in-
jected with both LPS and compound A compared with rats
injected with LPS alone (Fig. 8B). To further confirm the
inhibitory effects of compound A on LPS-induced microglia
activation, Western blot analysis was performed by using an
antibody against Iba-1, another marker of microglia. As
shown in Fig. 8C, compound A pretreatment obviously
suppressed LPS-induced elevation of Iba-1 expression in
primary neuron-glia cultures. These in vitro findings are
in agreement with results obtained from the in vivo stud-
ies. Taking these data together, clear evidence indicates
that compound A significantly inhibited the LPS-induced
neuroinflammation.
Discussion
Several lines of evidence presented in this study demon-
strate that compound A provided significant neuroprotection
on DA neurons against LPS-induced neurotoxicity through
the inhibition of IKK- and the suppression of proinflamma-
tory factor production. In in vitro studies, compound A pro-
tected DA neurons against LPS-induced neurodegeneration
in the mesencephalic neuron-glia cultures through inhibiting
the production of several proinflammatory factors. In animal
studies, compound A suppressed the LPS-induced activation
of microglia and significantly attenuated the LPS-induced
loss of nigral DA neurons. These findings suggest that anti-
A
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Fig. 4. Compound A inhibited NF-B sig-
naling pathway by Western blot analysis.
Primary microglia-enriched cultures were
pretreated with compound A (0.1 M) for
30 min and then stimulated with LPS for
15 min. The levels of phosphorylated p65
and IKK- compared with total p65 and
IKK- (A) and phosphorylated IB and
total IB relative to -actin (B) were in-
vestigated by Western blot analysis. Quan-
tified results are expressed as a percent-
age of the vehicle control cultures and are
the mean 	 S.E. from three independent
experiments. #, p  0.05 compared with
control cultures; , p  0.05 compared
with LPS-treated cultures.
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inflammatory properties underlie the neuroprotective effects
of compound A.
Substantial reports have documented that neuroinflamma-
tory mechanisms contribute to the cascades leading to neu-
ronal degeneration (Gao and Hong, 2008). The innate im-
mune surveillance in the central nervous system is mediated
primarily by microglia. Once activated by immunological chal-
lenges, environmental stresses, and neuronal injuries, micro-
glia are considered to be closely associated with neuronal dam-
age, especially in neurodegenerative diseases (Ransohoff and
Perry, 2009). In this study, we found that compound A protected
DA neurons against LPS- and MPP-induced neurodegenera-
tion. LPS directly induces the activation of microglia and the
release of proinflammatory factors and consequently produces
DA neurotoxicity. In contrast, MPP directly damages DA neu-
rons and causes the release of toxic substances, which in turn
activate microglia, termed reactive microgliosis (Gao et al.,
2003b). Either kind of microglial activation induced by LPS and
MPP will further cause the DA neuronal loss in a “self-propel-
ling” way and finally result in progressive DA neurodegenera-
tion. However, without the presence of microglia, compound A
failed to exhibit any neuroprotection on DA neurons, suggesting
microglia participated in compound A-mediated neuroprotec-
tion. Based on these results, we concluded that compound A
exerted neuroprotection against LPS-induced neurotoxicity
through the inhibition of microglia activation.
Moreover, activated microglia induce neurodegeneration
via the release of many proinflammatory factors, including
cytokines such as TNF and IL-1, ROS, and reactive nitro-
gen species such as superoxide and NO. Analysis of postmor-
tem brains indicated that microglia activation, elevated pro-
duction of ROS, and proinflammatory factors such as TNF,
IL-1, and NO have been discerned in the SN (McGeer et al.,
1988). Therefore, inhibition of these proinflammatory factors
can be beneficial for combating PD. In accordance with pre-
vious findings that compound A reduced the production of
TNF and IL-6 in a mouse model of acute ischemia–reperfu-
sion injury (Moss et al., 2007), we found compound A de-
creased the production of TNF, IL-1, and NO (Fig. 3).
These findings suggest that the inhibition of microglia acti-
vation and the decrease of proinflammatory factors contrib-
ute to compound A-mediated neuroprotection on DA neurons.
NF-B is known to play an important role in regulating
many genes involved in cell survival, immunity, and inflam-
mation (Moynagh, 2005; Hoffmann and Baltimore, 2006). For
instance, NF-B activation suppresses TNF-induced apop-
tosis in various cell types (Van Antwerp et al., 1996). NF-B
is broadly expressed in the central nervous system, including
neurons and glia. Recently, increasing emphasis has been
placed on the role of NF-B in the innate immune system.
NF-B is the most important transcription factor in inflam-
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Fig. 5. Compound A suppressed MAPK phosphorylation in activated microglia by Western blot analysis. Primary microglia-enriched cultures were
pretreated with compound A (0.1 M) for 30 min and then stimulated with LPS for 15 min. After the treatment, the whole cell protein was harvested.
A, the levels of phosphorylated MAPKs (ERK1/2, p38, and JNK) compared with total MAPKs were investigated by Western blot analysis.
B, autoradiographs were analyzed by densitometry. Quantified results are expressed as a percentage of the vehicle control cultures and are the mean 	
S.E. from three independent experiments. #, p  0.05 compared with control cultures; , p  0.05 compared with LPS-treated cultures.
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proinflammatory factors such as NO, TNF, and IL-1 (Jana
et al., 2001; Lee et al., 2004; Moynagh, 2005; Moriyama et al.,
2006). Nurr1, an orphan nuclear receptor, exerts anti-inflam-
matory effects by docking to NF-B-p65 on target inflamma-
tory gene promoters, recruiting the CoREST corepressor
complex, and subsequently resulting in clearance of NF-B-
p65 and transcriptional repression in astrocytes and micro-
glia. By reducing NF-B-mediated production of proinflam-
matory and neurotoxic factors, Nurr1 protects against loss of
DA neurons in PD (Saijo et al., 2009). Moreover, several lines
of evidence show that selective inhibition of NF-B activation
prevented DA neuronal loss against MPTP-intoxicated PD
mice (Ghosh et al., 2007). Thus, attempts to develop drugs
targeting NF-B for the treatment of neurodegenerative dis-
eases have become an area of great interest.
Given the marked inhibition of compound A on the produc-
tion of several proinflammatory mediators in microglia (Fig.
3), we therefore investigated the effects of compound A on
LPS-induced activation of NF-B and pinpointed the target-
ing site responsible for neuroprotective effects of compound A
on LPS- and MPTP-induced neurotoxicity. In resting condi-
tions, NF-B is sequestered in the cytoplasm by binding to its
inhibitor IB. In response to inflammatory stimuli, IBs are
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Fig. 6. Compound A attenuated LPS-induced production of ROS
through the inhibition of NADPH oxidase. Primary microglia-
enriched cultures were pretreated with compound A (0.1 M) for
30 min followed by LPS treatment. A and B, the release of super-
oxide was determined immediately by measuring the SOD-inhib-
itable reduction of WST-1 (A), and the levels of intracellular ROS
were detected with DCFH-DA (B). After LPS treatment for 15
min, subcellular fractions were isolated for Western blot analysis
for p47PHOX levels in membrane and cytosolic fractions of micro-
glia. Lanes C, cytosolic extract; M, membrane extract. C, -actin
and gp91PHOX were used as internal cytosolic and membrane
controls, respectively. Results are expressed as a percentage of the
vehicle control cultures and are the mean 	 S.E. from three
independent experiments performed in triplicate. #, p  0.05
compared with control cultures; , p  0.05 compared with LPS-
treated cultures.
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plex, followed by the release and translocation of NF-B
dimers (p50 and p65) to the nucleus and thus regulating the
expression of target genes. IKK complex is comprised of two
catalytic subunits, IKK- and IKK-, and a regulatory sub-
unit, IKK-
/NEMO (Yamamoto and Gaynor, 2004). Despite
high sequence homology and similar structural domains be-
tween the two catalytic subunits, IKK- has a 20- to 50-fold
higher level of kinase activity for IB than does IKK- (Li et
al., 1999). IKK- knockout mice have completely compro-
mised the NF-B pathway and die in utero of liver failure
from massive hepatocyte apoptosis (Li et al., 1999). In addi-
tion, the conditional knockout of the IKK- gene in myeloid-
lineage cells, including microglia, reduced IKK activity in
cultured primary microglia and blunted LPS-induced proin-
flammatory gene expression. Importantly, mice with defi-
cient IKK- genes are more resistant to kainic acid-induced
hippocampal neuronal death and revealed decreased glial
activation and expression of proinflammatory genes such as
TNF and IL-1 (Cho et al., 2008).
Compound A has been reported to specifically inhibit
IKK- to suppress NF-B signaling pathway and provide
cardioprotection (Ziegelbauer et al., 2005; Moss et al., 2007,
2008). In the present study, we found that compound A
significantly suppressed LPS-elicited phosphorylation of p65
and IKK- in the primary microglia-enriched cultures (Fig.
4A) and stabilized the inhibitor IB (Fig. 4B), which in turn
will prevent the nuclear translocation of the NF-B p50–p65
complex.
In addition to IKK- inhibition, compound A suppressed
LPS-induced phosphorylation of MAPKs including ERK1/2,
p38 MAPK, and JNK in microglia (Fig. 5). Based on previous
work from Ziegelbauer et al. (2005), compound A inhibited
human recombinant IKK- with a Ki of 2 nM for ATP and 4
nM for the substrate GST-IkB, whereas it inhibited IKK-
at higher concentrations (Ki for ATP: 135 nM), but did not
inhibit (IC50  10 M) MAPK kinase 4, MAPK kinase 7,
ERK-1, phosphoinositide 3-kinase 
, protein kinase A, and
protein kinase C (Ziegelbauer et al., 2005). Therefore, the
observed inhibition of MAPK by compound A in this study
may be secondary to its suppression on NF-B. Certainly,
there is close cross-talk among key inflammatory signaling
pathways during inflammation. For example, TNF, an im-
portant downstream product of NF-B activation, can acti-
vate ERK1/2 in keratinocytes during epidermal inflamma-
tion or induce a more than 10-fold increase in p38 MAPK
phosphorylation in neutrophil (Lokuta and Huttenlocher,
2005).
We also observed the unexpected inhibition of compound A
on NADPH oxidase (Fig. 6), a key superoxide-generating
enzyme during inflammation in various immune cells such as
microglia, macrophages, and neutrophils (Gao et al., 2002).
The treatment of compound A suppressed LPS-induced
p47PHOX translocation from cytosol to the cell membrane and
led to the reduction in ROS production from microglia (Fig.
6). There was overwhelming evidence indicating that ROS
can induce the activation of MAPK cascades and NF-B
pathway in activated microglia (Ramanan et al., 2008). On
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Fig. 7. Compound A attenuated DA neuronal
loss in the SN induced by LPS in vivo. A, the
treatment schedule of LPS-intoxicated rats with
compound A is shown. Rats were pretreated with
compound A (1 mg/kg/day s.c.) before a single
intranigral injection of LPS (5 g) into the SN
pars compacta on the right side of the rat brain.
Seven days after LPS injection, brains were har-
vested and sectioned. B and C, the sections were
immunostained with an anti-TH antibody (B)
and the number of TH-positive neurons in the
SN was counted (C). Scale bar, 200 m. Results
are expressed as a percentage of the TH-positive
number of the vehicle control group and are the
mean 	 S.E. from six rats. #, p  0.05 compared
with control groups; , p  0.05 compared with
LPS-treated groups.
Compound A Protects Dopamine Neurons Against Inflammation 831
ulatory subunit of the IKK complex, have impaired activation
of neutrophil NADPH oxidase (Singh et al., 2009). Currently,
it is not clear whether compound A at the concentration used
in this study directly interacts with one or more subunits of
NADPH oxidase to affect its activation. Further studies are
warranted to define precise mechanisms underlying the in-
hibition of compound A on NADPH oxidase.
Taken together, the inhibitory effects of compound A on
LPS-induced activation of NF-B pathways are responsible
mainly for the neuroprotection of compound A. The inhibi-
tion, either direct or indirect, of compound A on NADPH
oxidase partly contributes to the neuroprotective effect of
compound A, which reinforces the critical role of oxidative
damage in inflammation-mediated neurodegeneration. In
summary, our studies not only indicate an important contri-
bution of NF-B-mediated inflammatory process in PD neu-
rodegeneration, but also imply that modulation of the NF-B
pathway by using drugs such as compound A may potentially
better treat PD patients.
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of Iba-1 were determined by Western blot analysis. Quantified results are expressed as a percentage of the vehicle control cultures and are the mean 	
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